Sangamo Therapeutics (SGMO) – Research Analysts’ Recent Ratings Updates

Sangamo Therapeutics (NASDAQ: SGMO) has recently received a number of price target changes and ratings updates:

• 5/10/2023 – Sangamo Therapeutics had its price target lowered by analysts at Truist Financial Co. from $16.00 to $8.00.
• 5/1/2023 – Sangamo Therapeutics had its price target lowered by analysts at HC Wainwright from $15.00 to $5.00.
• 4/28/2023 – Sangamo Therapeutics was downgraded by analysts at Bank of America Co. from a “neutral” rating to an “underperform” rating. They now have a $1.50 price target on the stock, down previously from $5.00.
• 4/28/2023 – Sangamo Therapeutics had its price target lowered by analysts at Stifel Nicolaus from $4.20 to $3.90.
• 3/16/2023 – Sangamo Therapeutics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Sangamo Therapeutics Stock Down 0.8 %

Shares of NASDAQ:SGMO opened at $1.27 on Thursday. The firm has a market capitalization of $217.77 million, a PE ratio of -1.02 and a beta of 1.07. Sangamo Therapeutics, Inc. has a twelve month low of $1.18 and a twelve month high of $6.42. The company has a 50-day moving average price of $1.78 and a two-hundred day moving average price of $2.86.

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) last issued its earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. Sangamo Therapeutics had a negative net margin of 172.76% and a negative return on equity of 61.19%. The firm had revenue of $27.23 million during the quarter, compared to analyst estimates of $26.86 million. During the same quarter last year, the business earned ($0.26) earnings per share. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Analysts anticipate that Sangamo Therapeutics, Inc. will post -1.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of large investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Sangamo Therapeutics by 15.4% in the third quarter. BlackRock Inc. now owns 14,264,458 shares of the biopharmaceutical company’s stock valued at $69,894,000 after acquiring an additional 1,898,292 shares during the period. Vanguard Group Inc. boosted its position in shares of Sangamo Therapeutics by 10.5% in the third quarter. Vanguard Group Inc. now owns 12,731,109 shares of the biopharmaceutical company’s stock valued at $62,383,000 after acquiring an additional 1,205,951 shares during the period. State Street Corp boosted its position in shares of Sangamo Therapeutics by 25.3% in the first quarter. State Street Corp now owns 7,775,327 shares of the biopharmaceutical company’s stock valued at $45,175,000 after acquiring an additional 1,570,740 shares during the period. Credit Suisse AG raised its stake in Sangamo Therapeutics by 0.3% in the first quarter. Credit Suisse AG now owns 3,819,113 shares of the biopharmaceutical company’s stock valued at $6,722,000 after purchasing an additional 10,967 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Sangamo Therapeutics by 12.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,444,283 shares of the biopharmaceutical company’s stock valued at $10,815,000 after purchasing an additional 373,442 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors.

Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.